Slide 1: Q3 2023 Results
October 26, 2023 Q3 2023 Results Stephan Tanda, President & CEO and Bob Kuhn, Executive Vice President and CFO APTAR COMMUNICATIONS GUIDEBOOK
Slide 2: Forward Looking Statements & Non-GAAP Financial Measures
Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based
Slide 3: Q3 2023 Financial Highlights
Q3 2023 Financial Highlights Highlights: +7% Reported Sales Growth +2% Core Sales Growth* • Delivered another quarter of strong, double-digit adjusted EPS growth, driven by increased core sales in our proprietary pharma dosing and dispensing systems and the success of our beauty dispensing solutions
Slide 4: Recent Innovations and Solutions on the Market
Recent Innovations and Solutions on the Market Aptar Pharma Aptar Beauty Aptar Closures • Aptar’s patented, intuitive and more consumer- • Aptar’s fragrance and lotion pumps are featured on • McCormick is now featuring a bi-injected friendly Lateral Control System technology - a Jean Paul Gaultier D
Slide 5: Third Quarter 2023 Reported Results
Third Quarter 2023 Reported Results Q3 Highlights • Aptar Pharma’s performance was driven by strong double-digit core sales growth for proprietary drug delivery systems • Aptar Beauty’s core sales growth was driven by ongoing strength in beauty dispensing solutions for prestige and mass fragrance •
Slide 6: Third Quarter 2023 Adj. EPS and Adj. EBITDA
Third Quarter 2023 Adj. EPS and Adj. EBITDA Adjustments: • 2022: Restructuring Initiatives of $2.3 mil; Net investment gain of ($0.6) mil; Realized gain included in net investment gain of $0.4 mil; Transaction costs related to acquisitions of $0.2 mil • 2023: Restructuring Initiatives of $6.2 mil; N
Slide 7: Nine Months Year-to-Date 2023 Reported Results
Nine Months Year-to-Date 2023 Reported Results YTD Highlights • Aptar had a strong first nine months of the year due to the growth of our proprietary pharma drug delivery systems and our fragrance dispensing technologies * See accompanying slide titled: Forward Looking Statements & Non-GAAP Financia
Slide 8: Nine Months Year-to-Date 2023 Adj. EPS and Adj. EBITDA
Nine Months Year-to-Date 2023 Adj. EPS and Adj. EBITDA Adjustments: • 2022: Restructuring Initiatives of $3 mil; Net investment loss of $1.1 mil; Realized gain included in net investment loss of $1.2 mil; Transaction costs related to acquisitions of $0.2 mil • 2023: Restructuring Initiatives of $19.
Slide 9: Outlook
Outlook Outlook Highlights Earnings Per Share • Expect our proprietary pharma drug delivery dispensing systems to continue to grow $1.40 $1.20 $1.06 – $1.14 24-26% • Anticipate sales for fragrance dispensing solutions to finish strong in 2023 $1.00 $0.94 $0.89 $0.80 Q4 Expected • Beauty and Closures
Slide 10: Follow us on:
265 Exchange Drive Suite 301 Crystal Lake, IL 60014 +1-815-477-0424 Aptar.com Follow us on: 10